• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多功能 HER2 特异性 Affibody 分子的设计、合成与生物评价及其用于分子成像。

Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.

机构信息

Department of Radiology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

出版信息

Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1864-73. doi: 10.1007/s00259-009-1176-z. Epub 2009 Jun 6.

DOI:10.1007/s00259-009-1176-z
PMID:19504093
Abstract

PURPOSE

The purpose of this study was to design and evaluate a novel platform for labelling of Affibody molecules, enabling both recombinant and synthetic production and site-specific labelling with (99m)Tc or trivalent radiometals.

METHODS

The HER2-specific Affibody molecule PEP05352 was made by peptide synthesis. The chelator sequence SECG (serine-glutamic acid-cysteine-glycine) was anchored on the C-terminal to allow (99m)Tc labelling. The cysteine can alternatively serve as a conjugation site of the chelator DOTA for indium labelling. The resulting (99m)Tc- and (111)In-labelled Affibody molecules were evaluated both in vitro and in vivo.

RESULTS

Both conjugates retained their capacity to bind to HER2 receptors in vitro and in vivo. The tumour to blood ratio in LS174T xenografts was 30 at 4 h post-injection for both conjugates. Biodistribution data showed that the (99m)Tc-labelled Affibody molecule had a fourfold lower kidney accumulation compared with the (111)In-labelled Affibody molecule while the accumulation in other organs was similar. Gamma camera imaging of the conjugates could clearly visualise the tumours 4 h after injection.

CONCLUSION

Incorporation of the C-terminal SECG sequence in Affibody molecules provides a general multifunctional platform for site-specific labelling with different nuclides (technetium, indium, gallium, cobalt or yttrium) and for a flexible production (chemical synthesis or recombinant).

摘要

目的

本研究旨在设计和评估一种新型的亲和体分子标记平台,使其能够进行重组和合成生产,并实现(99m)Tc 或三价放射性金属的定点标记。

方法

HER2 特异性亲和体分子 PEP05352 通过肽合成制备。螯合剂序列 SECG(丝氨酸-谷氨酸-半胱氨酸-甘氨酸)连接在 C 末端,以允许(99m)Tc 标记。该半胱氨酸也可以作为螯合剂 DOTA 的缀合位点,用于铟标记。所得(99m)Tc 和(111)In 标记的亲和体分子在体外和体内进行了评估。

结果

两种缀合物在体外和体内均保留了与 HER2 受体结合的能力。在 LS174T 异种移植瘤中,两种缀合物在注射后 4 小时的肿瘤与血液比分别为 30。生物分布数据表明,与(111)In 标记的亲和体分子相比,(99m)Tc 标记的亲和体分子的肾脏积累降低了四倍,而其他器官的积累则相似。注射后 4 小时,两种缀合物的伽马相机成像均能清晰地显示肿瘤。

结论

在亲和体分子中引入 C 末端 SECG 序列为不同核素(锝、铟、镓、钴或钇)的定点标记以及灵活的生产(化学合成或重组)提供了一个通用的多功能平台。

相似文献

1
Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.多功能 HER2 特异性 Affibody 分子的设计、合成与生物评价及其用于分子成像。
Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1864-73. doi: 10.1007/s00259-009-1176-z. Epub 2009 Jun 6.
2
Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.DOTA 螯合剂位置对 (111)In 标记的合成抗 HER2 亲和体分子的生物分布和靶向特性的影响。
Bioconjug Chem. 2012 Aug 15;23(8):1661-70. doi: 10.1021/bc3002369. Epub 2012 Jul 17.
3
Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.评估一种将N端HEHEHE标签与GGGC螯合剂相结合的HER2靶向亲和体分子,用于在C端进行99mTc标记。
Tumour Biol. 2012 Jun;33(3):641-51. doi: 10.1007/s13277-011-0305-z. Epub 2012 Jan 17.
4
Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.**分子设计和优化** **99mTc** **标记的重组亲和体分子可改善其生物分布和成像特性。**
J Nucl Med. 2011 Mar;52(3):461-9. doi: 10.2967/jnumed.110.083592. Epub 2011 Feb 14.
5
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.使用含有99mTc螯合巯基乙酰-甘氨酰-甘氨酰-甘氨酰(MAG3)序列的合成亲和体分子对HER2表达肿瘤进行成像。
Eur J Nucl Med Mol Imaging. 2007 May;34(5):722-733. doi: 10.1007/s00259-006-0266-4. Epub 2006 Dec 5.
6
Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging.99mTc-肽-ZHER2:342 Affibody®分子的体内分子成像评价。
Br J Radiol. 2014 Jan;87(1033):20130484. doi: 10.1259/bjr.20130484. Epub 2013 Nov 22.
7
Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.肾摄取降低的99mTc标记亲合体分子的研发及临床前特性研究
Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2245-55. doi: 10.1007/s00259-008-0845-7. Epub 2008 Jul 2.
8
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.用一种位点特异性99mTc标记的重组亲和体分子ZHER2:2395靶向HER2表达肿瘤,该亲和体分子C端经工程改造含有半胱氨酸。
J Nucl Med. 2009 May;50(5):781-9. doi: 10.2967/jnumed.108.056929. Epub 2009 Apr 16.
9
Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging.111In 标记的双螺旋和三螺旋 Affibody 分子的体内分子成像的直接比较。
Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):693-702. doi: 10.1007/s00259-011-2016-5. Epub 2011 Dec 15.
10
Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.使用特异性标记的抗 EGFR 111In-DOTA-Z EGFR:2377 Affibody 分子对小鼠异种移植中的 EGFR 表达进行成像:注射示踪剂量的方面。
Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):613-22. doi: 10.1007/s00259-009-1283-x. Epub 2009 Oct 17.

引用本文的文献

1
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.探索PD-1/PD-L1成像示踪剂领域:从挑战到机遇
Front Med (Lausanne). 2024 Jun 7;11:1401515. doi: 10.3389/fmed.2024.1401515. eCollection 2024.
2
Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation.用于提高亲和体分子对B7-H3成像亲和力的方法比较:二聚化和亲和力成熟
EJNMMI Radiopharm Chem. 2024 Apr 16;9(1):30. doi: 10.1186/s41181-024-00261-3.
3
Preclinical Evaluation of Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake.

本文引用的文献

1
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.用一种位点特异性99mTc标记的重组亲和体分子ZHER2:2395靶向HER2表达肿瘤,该亲和体分子C端经工程改造含有半胱氨酸。
J Nucl Med. 2009 May;50(5):781-9. doi: 10.2967/jnumed.108.056929. Epub 2009 Apr 16.
2
On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.关于用于HER2表达肿瘤PET成像的示踪剂选择:在小鼠异种移植模型中对124I标记的亲和体分子与曲妥珠单抗的直接比较。
J Nucl Med. 2009 Mar;50(3):417-25. doi: 10.2967/jnumed.108.057919. Epub 2009 Feb 17.
3
Tc-ZHER2:41071 的临床前评估,一种基于第二代亲和体的 HER2 可视化成像探针,具有低肾摄取率。
Int J Mol Sci. 2021 Mar 9;22(5):2770. doi: 10.3390/ijms22052770.
4
Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers.基于人乳头瘤病毒的免疫诊断和免疫治疗在 HPV 诱导癌症中的应用。
Front Immunol. 2021 Jan 8;11:586796. doi: 10.3389/fimmu.2020.586796. eCollection 2020.
5
Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules.几种化合物和药物对放射性标记的亲和体分子肾脏摄取的影响。
Molecules. 2020 Jun 9;25(11):2673. doi: 10.3390/molecules25112673.
6
Affibody Molecules as Targeting Vectors for PET Imaging.作为正电子发射断层显像(PET)成像靶向载体的亲和体分子
Cancers (Basel). 2020 Mar 11;12(3):651. doi: 10.3390/cancers12030651.
7
On the prevention of kidney uptake of radiolabeled DARPins.关于预防放射性标记的设计型锚蛋白重复蛋白被肾脏摄取
EJNMMI Res. 2020 Feb 4;10(1):7. doi: 10.1186/s13550-020-0599-1.
8
Preclinical evaluation of Tc direct labeling Z for HER2 positive tumors imaging.用于HER2阳性肿瘤成像的锝直接标记物Z的临床前评估。
Oncol Lett. 2018 Oct;16(4):5361-5366. doi: 10.3892/ol.2018.9279. Epub 2018 Aug 8.
9
Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe.评价 HER2 特异性肽配体作为放射性标记成像探针的应用。
Sci Rep. 2018 Feb 14;8(1):2998. doi: 10.1038/s41598-018-21283-3.
10
Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.HPMA共聚物-表柔比星缀合物的铟基和碘基标记:结构对体内命运的影响
J Control Release. 2016 Aug 10;235:306-318. doi: 10.1016/j.jconrel.2016.06.004. Epub 2016 Jun 4.
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.
化合价和标记化学对使用放射性碘化HER2结合亲和体分子进行体内靶向的影响。
Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):692-701. doi: 10.1007/s00259-008-1003-y. Epub 2008 Dec 10.
4
Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.含赖氨酸的巯基乙酰基螯合剂对99mTc标记的抗HER2亲和体分子生物分布的影响。
Bioconjug Chem. 2008 Dec;19(12):2568-76. doi: 10.1021/bc800244b.
5
Imaging of HER-2 overexpression in tumors for guiding therapy.肿瘤中HER-2过表达的成像用于指导治疗。
Curr Pharm Des. 2008;14(28):2999-3019. doi: 10.2174/138161208786404290.
6
Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.用于亲和体分子位点特异性标记的CHX-A'' DTPA马来酰亚胺衍生物的评估。
Bioconjug Chem. 2008 Aug;19(8):1579-87. doi: 10.1021/bc800110y. Epub 2008 Jul 12.
7
Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.肾摄取降低的99mTc标记亲合体分子的研发及临床前特性研究
Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2245-55. doi: 10.1007/s00259-008-0845-7. Epub 2008 Jul 2.
8
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.用于生物分子放射性标记和金属放射性核素靶向递送的双功能偶联剂。
Adv Drug Deliv Rev. 2008 Sep;60(12):1347-70. doi: 10.1016/j.addr.2008.04.006. Epub 2008 Apr 23.
9
Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold.替代结合蛋白:由小三螺旋束支架开发的亲合体结合蛋白。
FEBS J. 2008 Jun;275(11):2668-76. doi: 10.1111/j.1742-4658.2008.06438.x. Epub 2008 Apr 24.
10
PET (positron emission tomography) imaging of biomolecules using metal-DOTA complexes: a new collaborative challenge by chemists, biologists, and physicians for future diagnostics and exploration of in vivo dynamics.使用金属-DOTA配合物对生物分子进行正电子发射断层扫描(PET)成像:化学家和生物学家以及物理学家在未来诊断和体内动力学探索方面面临的新合作挑战。
Org Biomol Chem. 2008 Mar 7;6(5):815-28. doi: 10.1039/b718157b. Epub 2008 Feb 1.